Get the App
Join our growing community to challenge mainstream media bias and fix the news
Gilead stock rise not as bullish after Remdesivir trial in China ’Flops’

Gilead stock rise not as bullish after Remdesivir trial in China ’Flops’

A clinical trial in China of Gilead’s Remdesivir is cut short due to disappointing expectations, prompting a sharp response from Gilead explaining the trial was cut short due to the low amount of trial participants. Gilead’s stock takes a minor hit.

Steve
Steve
Top in Business